On the stock market since 2010, it operates in the world of health and science. It has 327 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Average growth of 70% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Sales run at $81.7M a year. A small number, but proof the product has real buyers.
A loss of $227.4M against $81.7M in annual sales.
At the current pace of spending, the cash lasts about 1.3 years. After that, the company needs to find new money.
On our five-subject report card, ZGNX sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: ZGNX is a high-risk stock — not yet profitable, and its future rides on its product catching on.